Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL
06/29/2020
Arnon P. Kater, MD, PhD, Professor of Hematology, Amsterdam University Medical Center, the Netherlands, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax monotherapy in patients with relapsed/refractory CLL. These results were presented at the virtual 2020 EHA Annual Congress.